Drug Trial Radar · NCT03689010
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,116
Actual
Start
Dec 12, 2017
Primary completion
Aug 9, 2018
Study completion Sep 28, 2018
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
Conditions
- Rosacea
Interventions
Azelaic acid foam 15%Drug
Azelaic acid foam 15%
Finacea® (Azelaic acid Foam) 15%Drug
Azelaic acid foam 15%
Vehicle of the test productDrug
Vehicle of the test product
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in the inflammatory lesion countsTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Catawba Research, LLC
Charlotte, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.